Department of Thoracic Oncological Surgery, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang province 310022, China; Zhejiang Provincial Research Center for Upper Gastrointestinal Tract Cancer, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang province 310022, China; The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang province 310053, China.
Department of Thoracic Oncological Surgery, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang province 310022, China.
Int Immunopharmacol. 2023 Aug;121:110459. doi: 10.1016/j.intimp.2023.110459. Epub 2023 Jun 10.
No study has reported the clinical outcomes of comprehensive nutritional index (CNI) in esophageal squamous cell carcinoma (ESCC) receiving neoadjuvant immunotherapy combined with chemotherapy (nICT).
This retrospective study involved 233 ESCC patients who underwent nICT. Principal component analysis was performed to establish the CNI based on 5 indexes including body mass index, usual body weight percentage, total lymphocyte count, albumin and hemoglobin. The relationships between the CNI and therapeutic response, postoperative complications and prognosis were analyzed.
One hundred and forty-nine and 84 patients were assigned to the high and low CNI group, respectively. The incidences of respiratory complications (33.3% vs. 18.8%, P = 0.013) and vocal cord paralysis (17.9% vs. 8.1%, P = 0.025) in low CNI were significantly higher than those in high group, respectively. Seventy (30.0%) patients achieved pathological complete response (pCR). High CNI patients achieved a better pCR rate than those with low CNI (41.6% vs. 9.5%, P < 0.001). The CNI served as an independent pCR predictor [odds ratio (OR) = 0.167, 95% confidence interval (CI) = 0.074-0.377, P < 0.001)]. High CNI patients had better 3-year disease-free survival (DFS) (85.4% vs. 52.6%, P < 0.001) and overall survival (OS) (85.5% vs. 64.5%, P < 0.001) than those with low CNI, respectively. The CNI served as an independent prognostic score regarding DFS [hazard ratio (HR) = 3.878, 95% CI = 2.214-6.792, P < 0.001)] and OS (HR = 4.386, 95% CI = 2.006-9.590, P < 0.001).
Based on nutrition-related indicators, the pretreatment CNI serves as a sensitive and effective predictor of therapeutic response, postoperative complications and prognosis in ESCC receiving nICT.
尚无研究报道新辅助免疫联合化疗(nICT)治疗食管鳞状细胞癌(ESCC)患者的综合营养指数(CNI)的临床结局。
本回顾性研究纳入 233 例接受 nICT 的 ESCC 患者。基于体重指数、常用体重百分比、总淋巴细胞计数、白蛋白和血红蛋白 5 项指标,采用主成分分析建立 CNI。分析 CNI 与治疗反应、术后并发症和预后的关系。
149 例和 84 例患者分别被分配至高 CNI 组和低 CNI 组。低 CNI 组呼吸并发症(33.3%比 18.8%,P=0.013)和声带麻痹(17.9%比 8.1%,P=0.025)的发生率明显高于高 CNI 组。70 例(30.0%)患者达到病理完全缓解(pCR)。高 CNI 患者的 pCR 率高于低 CNI 患者(41.6%比 9.5%,P<0.001)。CNI 是 pCR 的独立预测因素[比值比(OR)=0.167,95%置信区间(CI)=0.074-0.377,P<0.001)]。高 CNI 患者的 3 年无病生存率(DFS)(85.4%比 52.6%,P<0.001)和总生存率(OS)(85.5%比 64.5%,P<0.001)均优于低 CNI 患者。CNI 是 DFS(风险比[HR]=3.878,95%CI=2.214-6.792,P<0.001)]和 OS(HR=4.386,95%CI=2.006-9.590,P<0.001)的独立预后评分。
基于营养相关指标,治疗前 CNI 可作为 ESCC 患者接受 nICT 治疗的治疗反应、术后并发症和预后的敏感、有效预测指标。